Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Pharmaceutical Statistics
|
January 8, 2013
Missing data in clinical trials: from clinical assumptions to statistical analysis using pattern mixture models
Bohdana Ratitch, Michael O'Kelly, Robert Tosiello
International Journal of Chronic Obstructive Pulmonary Disease
|
December 28, 2018
Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4
Jill Ohar, Robert Tosiello, Thomas Goodin, et al.
Respiratory Research
|
December 6, 2017
Dose selection for glycopyrrolate/eFlow<sup>®</sup> phase III clinical studies: results from GOLDEN (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer) phase II dose-finding studies
James F Donohue, Thomas Goodin, Robert Tosiello, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)
|
February 19, 2019
Efficacy and Safety of Nebulized Glycopyrrolate/eFlow® Closed System in Patients with Moderate-to-Very-Severe Chronic Obstructive Pulmonary Disease with Pre-Existing Cardiovascular Risk Factors
Gary T Ferguson, Robert Tosiello, Shahin Sanjar, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery
|
October 3, 2006
Randomized double-blind study comparing 7- and 10-day regimens of faropenem medoxomil with a 10-day cefuroxime axetil regimen for treatment of acute bacterial sinusitis
John Upchurch, Michael Rosemore, Robert Tosiello, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
October 3, 2018
Effect of background long-acting beta<sub>2</sub>-agonist therapy on the efficacy and safety of a novel, nebulized glycopyrrolate in subjects with moderate-to-very-severe COPD
Edward M Kerwin, Robert Tosiello, Barry Price, et al.
Expert Review of Anti-Infective Therapy
|
December 22, 2006
Faropenem medoxomil: a treatment option in acute bacterial rhinosinusitis
James A Hadley, Glenn S Tillotson, Robert Tosiello, et al.
Respiratory Medicine
|
September 19, 2017
Long-term safety of glycopyrrolate/eFlow<sup>®</sup> CS in moderate-to-very-severe COPD: Results from the Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer (GOLDEN) 5 randomized study
Gary T Ferguson, Thomas Goodin, Robert Tosiello, et al.
Respiratory Medicine
|
August 26, 2017
Efficacy and safety of glycopyrrolate/eFlow<sup>®</sup> CS (nebulized glycopyrrolate) in moderate-to-very-severe COPD: Results from the glycopyrrolate for obstructive lung disease via electronic nebulizer (GOLDEN) 3 and 4 randomized controlled trials
Edward Kerwin, James F Donohue, Thomas Goodin, et al.
Chest
|
December 3, 2014
One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD
James F Donohue, Nicola A Hanania, Barry Make, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Pharmaceutical Statistics
|
January 8, 2013
Missing data in clinical trials: from clinical assumptions to statistical analysis using pattern mixture models
Bohdana Ratitch, Michael O'Kelly, Robert Tosiello
International Journal of Chronic Obstructive Pulmonary Disease
|
December 28, 2018
Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4
Jill Ohar, Robert Tosiello, Thomas Goodin, et al.
Respiratory Research
|
December 6, 2017
Dose selection for glycopyrrolate/eFlow<sup>®</sup> phase III clinical studies: results from GOLDEN (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer) phase II dose-finding studies
James F Donohue, Thomas Goodin, Robert Tosiello, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)
|
February 19, 2019
Efficacy and Safety of Nebulized Glycopyrrolate/eFlow® Closed System in Patients with Moderate-to-Very-Severe Chronic Obstructive Pulmonary Disease with Pre-Existing Cardiovascular Risk Factors
Gary T Ferguson, Robert Tosiello, Shahin Sanjar, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery
|
October 3, 2006
Randomized double-blind study comparing 7- and 10-day regimens of faropenem medoxomil with a 10-day cefuroxime axetil regimen for treatment of acute bacterial sinusitis
John Upchurch, Michael Rosemore, Robert Tosiello, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
October 3, 2018
Effect of background long-acting beta<sub>2</sub>-agonist therapy on the efficacy and safety of a novel, nebulized glycopyrrolate in subjects with moderate-to-very-severe COPD
Edward M Kerwin, Robert Tosiello, Barry Price, et al.
Expert Review of Anti-Infective Therapy
|
December 22, 2006
Faropenem medoxomil: a treatment option in acute bacterial rhinosinusitis
James A Hadley, Glenn S Tillotson, Robert Tosiello, et al.
Respiratory Medicine
|
September 19, 2017
Long-term safety of glycopyrrolate/eFlow<sup>®</sup> CS in moderate-to-very-severe COPD: Results from the Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer (GOLDEN) 5 randomized study
Gary T Ferguson, Thomas Goodin, Robert Tosiello, et al.
Respiratory Medicine
|
August 26, 2017
Efficacy and safety of glycopyrrolate/eFlow<sup>®</sup> CS (nebulized glycopyrrolate) in moderate-to-very-severe COPD: Results from the glycopyrrolate for obstructive lung disease via electronic nebulizer (GOLDEN) 3 and 4 randomized controlled trials
Edward Kerwin, James F Donohue, Thomas Goodin, et al.
Chest
|
December 3, 2014
One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD
James F Donohue, Nicola A Hanania, Barry Make, et al.
Page
of 2